REVIEW
Toxic neuropathies and their treatment.
Baillière's Clinical Neurology 1995 November
Peripheral neuropathy triggered by therapeutic drugs, workplace chemicals and environmental pollutants continues to be one of the most common pathological responses of the human nervous system to chemical attack. While some agents seem to damage the nerve cell directly, and a few induce primary demyelination, the large majority produces distal axonal degeneration simultaneously in long peripheral nerves and spinal tracts. Glove-and-stocking sensory loss typically precedes the development of a similar distribution of motor weakness. Clinical signs usually appear weeks after exposure has commenced; the condition continues to evolve after chemical exposure has ceased, and recovery spans a period of months or years. Careful clinical and laboratory assessment is needed to identify environmental agents responsible for human neuropathy, and reports of cases that claim a chemical causation require verification from experimental animal studies of suspect agents. Treatment of peripheral neuropathy continues to be limited, although a new therapeutic approach to patients with neuropathy-producing heavy metal intoxication is promising. Novel methods to limit nerve degeneration and promote regeneration are under study, but none has produced a convincing therapeutic effect. These are urgently needed to prevent and control the neuropathies that limit the therapeutic usefulness of drugs used in cancer chemotherapy and AIDS treatment.
Full text links
Trending Papers
Management of Hemorrhagic Shock: Physiology Approach, Timing and Strategies.Journal of Clinical Medicine 2022 December 30
New antibiotics for Gram-negative pneumonia.European Respiratory Review : An Official Journal of the European Respiratory Society 2022 December 32
Migraine.Annals of Internal Medicine 2023 January 11
How to diagnose iron deficiency in chronic disease: A review of current methods and potential marker for the outcome.European Journal of Medical Research 2023 January 10
New therapies for obesity.Cardiovascular Research 2022 November 31
Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology.Swiss Medical Weekly 2023 January 7
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app